EQS-News
129 
0 Kommentare
Viromed Medical AG welcomes Dr. Thomas Gutschlag as new Investor
- Dr. Thomas Gutschlag joins Viromed as new investor.
- He acquired 100,000 shares from CEO Uwe Perbandt.
- Viromed focuses on cold plasma tech for medical use.
|
EQS-News: Viromed Medical AG / Key word(s): Miscellaneous Viromed Medical AG welcomes Dr. Thomas Gutschlag as new Investor |
Pinneberg, April 23, 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in wound healing, intensive care medicine and air disinfection, has gained Dr. Thomas Gutschlag, founder and Chairman of the Supervisory Board of Deutsche Rohstoff AG, as a new investor. In a first step, Dr. Gutschlag has acquired 100,000 shares in Viromed AG. The shares were provided by Uwe Perbandt, CEO of Viromed Medical AG, from his own holdings.
"Viromed's products with the underlying cold plasma technology have the potential to revolutionize medical applications. I am very excited to be able to support the future of this interesting company as an investor," says Thomas Gutschlag.
"We are delighted to welcome Thomas Gutschlag as a new investor with capital market experience and would like to thank him for his confidence in Viromed's products and our team," says Uwe Perbandt.
About cold plasma technology
Cold atmospheric plasma (CAP) is an innovative physical treatment method that is completely painless. The reactive species in cold plasma activate the release of cytokine proteins, which regulate
cell growth and differentiation. To improve blood circulation in skin areas and wounds, cold plasma stimulates angiogenesis, i.e. the formation of blood vessels from existing blood vessels. CAP
also inactivates viruses, bacteria (including multi-resistant pathogens) and spores in an uncomplicated and painless way. The use of cold plasma therefore has the potential to contribute to
aesthetic skin care and skin rejuvenation, reduce infections, accelerate healing processes and reduce the use of antibiotics.
About Viromed Medical AG
Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October
2022, focuses on the distribution of the innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. In doing so, Viromed can draw on a
broad customer base in the DACH region. Viromed Medical AG aims to further advance the use of CAP in medicine in the coming years and to realize corresponding growth potential.
The translation is provided for information purposes only.
In the event of any discrepancy between the German and English versions of this press release, the German version shall prevail.
Contact Viromed Medical AG
Uwe Perbandt
Management Board
Flensburger Straße 18
25421 Pinneberg
E-Mail: kontakt@viromed-medical.de
www.viromed-medical-ag.de
Media inquiries MC Services AG
Anne Hennecke / Dr. Kai Schmitz
E-Mail: Viromed.news@mc-services.eu
Phone: 0211-529252-104
23.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Viromed Medical AG |
| Flensburger Straße 18 | |
| 25421 Pinneberg | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A3MQR65 |
| WKN: | A3MQR6 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Tradegate Exchange |
| EQS News ID: | 2121840 |
| End of News | EQS News Service |
|
|
2121840 23.04.2025 CET/CEST
Diskutieren Sie über die enthaltenen Werte
URL kopieren
Per E-Mail teilen
Artikel drucken